Preliminary clinical evaluation of azapropazone in rheumatoid arthritis.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004123:Dimethylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007596:Joints / Q000187:drug effects; D008297:Male; D008314:Malonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000188:drug therapy; D010919:Placebos; D013997:Time Factors; D014227:Triazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D000893:Anti-Inflammatory Agents; D004123:Dimethylamines; D008314:Malonates; D010919:Placebos; D014227:Triazines